Goldman Sachs Group Inc Design Therapeutics, Inc. Transaction History

Goldman Sachs Group Inc

  • $613 Billion
  • Q4 2024

A detailed history of Goldman Sachs Group Inc transactions in Design Therapeutics, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 297,129 shares of DSGN stock, worth $1.36 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
297,129
Previous 275,532 7.84%
Holding current value
$1.36 Million
Previous $1.48 Million 23.68%
% of portfolio
0.0%
Previous 0.0%

Shares

20 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 11, 2025
BUY
$4.56 - $7.5 $98,482 - $161,977
21,597 Added 7.84%
297,129 $1.83 Million
Q3 2024

Nov 14, 2024
SELL
$3.19 - $5.88 $1.05 Million - $1.93 Million
-328,173 Reduced 54.36%
275,532 $1.48 Million
Q2 2024

Aug 13, 2024
BUY
$3.23 - $4.77 $314,760 - $464,831
97,449 Added 19.25%
603,705 $2.02 Million
Q1 2024

May 15, 2024
SELL
$2.27 - $4.03 $1.17 Million - $2.09 Million
-517,467 Reduced 50.55%
506,256 $2.04 Million
Q4 2023

Feb 13, 2024
BUY
$1.99 - $2.76 $1.15 Million - $1.6 Million
579,225 Added 130.31%
1,023,723 $2.71 Million
Q3 2023

May 14, 2024
SELL
$2.05 - $8.14 $1.19 Million - $4.71 Million
-579,225 Reduced 56.58%
444,498 $1.05 Million
Q3 2023

Nov 14, 2023
SELL
$2.05 - $8.14 $5,981 - $23,752
-2,918 Reduced 0.65%
444,498 $1.05 Million
Q2 2023

May 14, 2024
BUY
$4.99 - $7.64 $732,492 - $1.12 Million
146,792 Added 48.83%
447,416 $2.82 Million
Q2 2023

Aug 14, 2023
BUY
$4.99 - $7.64 $732,492 - $1.12 Million
146,792 Added 48.83%
447,416 $2.82 Million
Q1 2023

May 14, 2024
BUY
$5.5 - $9.77 $143,841 - $255,514
26,153 Added 9.53%
300,624 $1.73 Million
Q1 2023

May 11, 2023
BUY
$5.5 - $9.77 $143,841 - $255,514
26,153 Added 9.53%
300,624 $1.73 Million
Q4 2022

May 14, 2024
SELL
$7.86 - $17.2 $5.65 Million - $12.4 Million
-719,174 Reduced 72.38%
274,471 $2.82 Million
Q4 2022

Feb 13, 2023
SELL
$7.86 - $17.2 $5.65 Million - $12.4 Million
-719,174 Reduced 72.38%
274,471 $2.82 Million
Q3 2022

May 14, 2024
BUY
$14.09 - $25.57 $12.7 Million - $23.1 Million
902,408 Added 989.08%
993,645 $16.6 Million
Q3 2022

Nov 10, 2022
BUY
$14.09 - $25.57 $12.7 Million - $23.1 Million
902,408 Added 989.08%
993,645 $16.6 Million
Q2 2022

May 14, 2024
SELL
$9.91 - $17.33 $9.24 Million - $16.2 Million
-932,486 Reduced 91.09%
91,237 $1.28 Million
Q2 2022

Aug 15, 2022
SELL
$9.91 - $17.33 $256,619 - $448,760
-25,895 Reduced 22.11%
91,237 $1.28 Million
Q1 2022

May 16, 2022
BUY
$11.17 - $20.89 $550,613 - $1.03 Million
49,294 Added 72.66%
117,132 $1.89 Million
Q4 2021

Feb 14, 2022
BUY
$13.64 - $21.41 $173,282 - $271,992
12,704 Added 23.04%
67,838 $1.45 Million
Q3 2021

Nov 10, 2021
BUY
$13.99 - $20.03 $771,324 - $1.1 Million
55,134 New
55,134 $810,000

Others Institutions Holding DSGN

# of Institutions
97
Shares Held
32.1M
Call Options Held
4.6K
Put Options Held
2.6K
View Full List

About Design Therapeutics, Inc.

DSGN Quotes by TradingView
  • Ticker DSGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,807,900
  • Market Cap $256M
  • Description
  • Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ syste...
More about DSGN
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email